Please assess the completion status of the following clinical trial:

Trial Title: Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with histopathological confirmation of primary (or recurrent) invasive breast carcinoma and distant metastatic disease at diagnosis.~* Target tumor size ≤ 3.0 cm (T1-2b category);~* Morphological type: invasive breast cancer~* Luminal-type A (ER+, PR+, Her2/neu +1), HER+, luminal-type B (ER +/-, PR +/-, Her2/neu+1), or Triple negative breast carcinoma~* Measurable disease according to RECIST v1.1.~* Subjects over 45 years old.~* Subjects' ECOG Performance Status Scale is \< 2.~* Subjects' life expectancy more than 6 months.~* Platelet count ≥100,000/mm3.~* International normalized ratio of prothrombin time ≤1.8.~* Creatinine ≤1.9 mg/dL.~* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.~* Subjects are willing to sign an informed consent form.~Exclusion Criteria:~* T4 category with skin involvement.~* Regional lymph node metastases.~* Ductal carcinoma in situ.~* Inflammatory breast carcinoma.~* Patients with pre-irradiation of the breast.~* Acute infection disease.~* The presence of HIV, RW, HbsAg, HCV in the acute stage.~* Pregnancy or lactation.~* Serious competing (somatic) diseases incompatible according to the researcher with brachytherapy.~* Mental illness.~* Patients undergoing immunosuppressive and/or systemic corticosteroid treatment~* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.~* High probability of protocol non-compliance (in opinion of investigator).~* Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)~* Subjects not willing to sign an informed consent.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DaRT Seeds (Type: EXPERIMENTAL): Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds

Based on this trial design, predict the completion outcome and termination type (if applicable).